Journal of child and adolescent psychopharmacology最新文献

{"title":"Factors Influencing Medication Adherence in Adolescents with Psychiatric Disorders: Quantitative Results from a Multicenter Mixed-Methods Study.","authors":"Florian Handermann, Clara Both, Larissa Niemeyer, Lucca Schumm, Ralf W Dittmann, Alexander Häge, Konstantin Mechler","doi":"10.1177/10445463261485772","DOIUrl":"https://doi.org/10.1177/10445463261485772","url":null,"abstract":"<p><strong>Background: </strong>Medication-related attitudes are considered an important determinant of adherence to psychopharmacological treatment in adolescents. The Questionnaire on Attitudes Toward Treatment (QATT) was originally developed for adolescents with attention-deficit/hyperactivity disorder, but its applicability in transdiagnostic adolescent psychiatric populations has not been investigated. This study examined medication attitudes and factors associated with noncomplete medication adherence in a transdiagnostic sample of adolescents receiving psychopharmacological treatment.</p><p><strong>Methods: </strong>This secondary analysis included 75 adolescents (12-17 years) participating in the multicenter SEMA study (Subjective Experience and Medication Adherence in Adolescents with Psychiatric Disorders). Medication adherence was assessed using the Medication Adherence Report Scale (MARS) and the QATT, together with demographic and clinical variables. Adherence was classified as complete or noncomplete. Group comparisons of QATT scores and an exploratory multivariable logistic regression were performed to identify factors associated with noncomplete medication adherence.</p><p><strong>Results: </strong>Forty percent of participants were classified as not completely adherent. Higher QATT scores, indicating less favorable attitudes toward medication, were observed among older adolescents, inpatients, adolescents with internalizing disorders, and participants classified as not completely adherent. In the multivariable logistic regression, higher QATT total scores (odds ratio [OR] = 1.05, 95% confidence interval [CI]: 1.00-1.10; <i>p</i> = 0.048) and polypharmacy (OR = 3.64, 95% CI: 1.03-12.88; <i>p</i> = 0.046) were independently associated with noncomplete medication adherence.</p><p><strong>Conclusion: </strong>In this transdiagnostic adolescent psychiatric sample, less favorable medication attitudes, as assessed by the QATT, were associated with noncomplete medication adherence. Assessing medication attitudes may complement routine adherence assessment. Prospective studies are needed to further validate the QATT and determine its utility for identifying adolescents at risk of noncomplete medication adherence.</p>","PeriodicalId":15277,"journal":{"name":"Journal of child and adolescent psychopharmacology","volume":" ","pages":"10445463261485772"},"PeriodicalIF":1.8,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148880648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Letter:</i> Psychosis Following Hormonal Therapy in NAA15-Related Neurodevelopmental Disorder.","authors":"Carolina Christ, Rikhil Makwana, Frank S K Appah, Hanyin Cheng, Claudia Moreno, Elaine Marchi, Randie Harpell, Gholson J Lyon","doi":"10.1177/10445463261462385","DOIUrl":"10.1177/10445463261462385","url":null,"abstract":"","PeriodicalId":15277,"journal":{"name":"Journal of child and adolescent psychopharmacology","volume":" ","pages":"454-456"},"PeriodicalIF":1.8,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148277612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polygenic Risk for Insomnia in Relation to Sleep Disturbance and Psychiatric Characteristics in Youth with Mood Disorders.","authors":"Alexandra A Puchiele, Megan Mio, Mikaela K Dimick, Clement C Zai, Mark I Boulos, Jennifer S Rabin, Benjamin I Goldstein","doi":"10.1177/10445463261456656","DOIUrl":"10.1177/10445463261456656","url":null,"abstract":"<p><strong>Background: </strong>Sleep disturbance is common in youth with mood disorders and correlates with mood symptom burden. Insomnia polygenic risk scores (PRS), computed from adult genome-wide association study (GWAS) data, are associated with sleep disturbance among youth within the general population. However, no studies have examined insomnia-PRS in a clinical sample of youth with mood disorders.</p><p><strong>Methods: </strong>Participants included 374 youth aged 13-20 years, 247 with mood disorders (135 bipolar disorder [BD] and 112 major depressive disorder) and 127 controls. Insomnia-PRS was constructed using an adult insomnia GWAS (<i>N</i> = 360,738). Sleep disturbance was computed using the most severe lifetime insomnia and hypersomnia (i.e., excessive sleep) items from the Kiddie Schedule for Affective Disorders and Schizophrenia Depression Rating Scale. General linear models or logistic regressions examined main effects of insomnia-PRS on sleep disturbance and psychiatric characteristics (mood symptom severity, anxiety comorbidity, suicide risk, global functioning), controlling for age, sex, and genetic principal components.</p><p><strong>Results: </strong>Insomnia-PRS was higher in youth with mood disorders versus controls (<i>p</i> = 0.03, <i>d</i> = 0.24). Insomnia-PRS was associated with insomnia severity in youth with mood disorders (<i>p</i> = 0.03, <i>η_p²</i> = 0.02), and with mania severity in youth with BD (<i>p</i> = 0.03, <i>η_p²</i> = 0.03), although the insomnia severity finding did not survive Bonferroni correction. In sex-stratified analyses, insomnia-PRS was significantly associated with insomnia (<i>p</i> = 0.02, <i>η_p²</i> = 0.03), depression (<i>p =</i> 0.02, <i>η_p² =</i> 0.03), and mania (<i>p =</i> 0.02, <i>η_p²</i> = 0.05) severity in females but not males. There were no significant findings for excessive sleep.</p><p><strong>Conclusions: </strong>This study extends prior findings linking adult-derived insomnia-PRS with insomnia in youth with mood disorders, with evidence of differences related to sex and BD. These preliminary findings suggest that sleep and mood in youth may be sensitive to adult-derived insomnia-PRS.</p>","PeriodicalId":15277,"journal":{"name":"Journal of child and adolescent psychopharmacology","volume":" ","pages":"423-431"},"PeriodicalIF":1.8,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148211335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Cannabinoid-Based Products in Children and Adolescents with Autism Spectrum Disorder, Fragile X Syndrome and Rett Syndrome: A Systematic Review.","authors":"Silvia Boeri, Luca Bosisio, Giulia Prato, Marina Martinez Popple, Elisa De Grandis, Pasquale Striano, Timothy A Benke, Lino Nobili","doi":"10.1177/10445463261462382","DOIUrl":"10.1177/10445463261462382","url":null,"abstract":"<p><strong>Introduction: </strong>Neurodevelopmental disorders (NDDs), including Autism Spectrum Disorder (ASD), Fragile X syndrome (FXS), and Rett Syndrome (RTT), share impairments in cognitive and behavioral functioning and may involve an altered excitatory/inhibitory balance modulated by the endocannabinoid system. This systematic review evaluated the safety and efficacy of cannabinoid-based products (CBPs) in these pediatric NDDs.</p><p><strong>Methods: </strong>We conducted a systematic review according to Preferred Reporting Items of Systematic Reviews and Meta-Analyses (PRISMA) 2020, including randomized and nonrandomized studies of patients under 18 years treated with cannabidiol (CBD), cannabidivarin (CBDV), tetrahydrocannabinol (THC), or their combinations. Outcomes were adverse events (AEs) and treatment discontinuation, seizure reduction, and behavioral and cognitive changes. Study quality and certainty of evidence were assessed using design-specific risk-of-bias tools and the GRADE approach.</p><p><strong>Results: </strong>Seventeen studies (two randomized controlled trials, observational studies, and case series) met the inclusion criteria. Across diagnoses, CBPs were generally associated with mild-to-moderate AEs and low discontinuation rates. Descriptive pooled proportions suggested behavioral improvements in ASD and FXS and seizure reduction in RTT, with exploratory analyses indicating differential effects of CBD versus CBD + THC on behavioral and cognitive outcomes in ASD.</p><p><strong>Conclusion: </strong>CBPs may offer potential benefits for selected behavioral symptoms and comorbid epilepsy in pediatric NDDs, but current evidence is insufficient to support routine clinical use. High-quality randomized controlled trials with standardized outcome measures and long-term follow-up are needed to clarify efficacy, safety, and syndrome-specific effects.</p>","PeriodicalId":15277,"journal":{"name":"Journal of child and adolescent psychopharmacology","volume":" ","pages":"393-404"},"PeriodicalIF":1.8,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148308473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tool for Converting ADHD Rating Scales Scores Based on Individual Participant Data from 53 Randomized Controlled Trials of ADHD Medications.","authors":"Christos Christogiannis, Miguel Garcia-Argibay, Anneka Tomlinson, Sulagna Roy, Luis C Farhat, Guilherme Fusetto Veronesi, Valeria Parlatini, Alessio Bellato, Corentin J Gosling, Dimitris Mavridis, Orestis Efthimiou, Edoardo G Ostinelli, Andrea Cipriani, Samuele Cortese","doi":"10.1177/10445463261461541","DOIUrl":"10.1177/10445463261461541","url":null,"abstract":"<p><strong>Introduction: </strong>A variety of rating scales are currently being used to assess symptom severity and quantify symptoms change in attention-deficit/hyperactivity disorder (ADHD) research and clinical practice. This poses difficulties in interpreting scores from different scales in clinical practice and synthesizing data from studies using different scales. We aimed to develop algorithms for converting scores across the ADHD scales most often used in randomized controlled trials (RCTs) of ADHD medications in children/adolescents and adults, and to develop an online tool for implementing the algorithms.</p><p><strong>Methods: </strong>We analyzed individual participant data from RCTs of ADHD medications (32 RCTs in children/adolescents, 21 in adults), with data on at least two scales per participant at the same timepoint. We applied a series of competing models, that is, univariable and multivariable regression, random forests, and an equipercentile linkage approach, to link pairs of scales. To assess the error of the linking procedure and identify the optimal model, we calculated the median absolute error and <math><mrow><msup><mrow><mi>R</mi></mrow><mrow><mn>2</mn></mrow></msup></mrow></math> of all approaches by comparing the values predicted from the models to the observed ones. We subsequently developed a tool to implement the best algorithms.</p><p><strong>Results: </strong>We linked six commonly used ADHD scales, such as the ADHD Rating Scale (ADHD-RS-IV; investigator-rated) and the Conners' Parent Rating Scale (CPRS-R:S). Spline models most frequently yielded the lowest prediction error, outperforming alternative conversion algorithms for absolute scores in 6 out of 12 univariable models and 8 out of 12 multivariable models. The tool for scores conversion is available at ADHD_Scale_Conversion_Tool.</p><p><strong>Conclusions: </strong>Our linkage algorithms enable the comparison and harmonization of findings across studies using different ADHD rating scales. Translating scores across scales improves the interpretability of research findings, facilitates future evidence synthesis across studies, and may support clinical practice. Our online tool supports the practical uptake of our results.</p>","PeriodicalId":15277,"journal":{"name":"Journal of child and adolescent psychopharmacology","volume":" ","pages":"405-413"},"PeriodicalIF":1.8,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148277628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Testing a Developmental Cascade Model from Prenatal Maternal Emotion Dysregulation to Toddler Behavior Dysregulation Through Postnatal Parenting Stress and Infant Physiology.","authors":"Anna M Zhou, Nicolette C Molina, Sarah E Maylott, Anna M Compton, Dylan Neff, Mengyu Miranda Gao, Shane Denherder, Madeleine Bruce, K Lee Raby, Elisabeth Conradt, Sheila E Crowell","doi":"10.1177/10445463261463074","DOIUrl":"10.1177/10445463261463074","url":null,"abstract":"<p><strong>Objective: </strong>Early behavioral dysregulation places children at elevated risk for later psychopathology. Maternal emotion dysregulation during pregnancy is a transdiagnostic vulnerability that may shape child regulatory development through both prenatal biological influences and postnatal caregiving. However, less is known about the specific postnatal mechanisms through which prenatal emotion dysregulation confers risk for toddler behavioral dysregulation. This study examined whether prenatal maternal emotion dysregulation was associated with toddler behavioral dysregulation indirectly through infant parasympathetic regulation (baseline respiratory sinus arrhythmia; RSA) and postnatal parenting stress.</p><p><strong>Methods: </strong>Participants were 385 mothers and their infants recruited during the third trimester. At the third trimester, maternal emotion dysregulation was assessed using the Difficulties in Emotion Regulation Scale. At 7 months postpartum, parenting stress was measured using the Parenting Stress Index, and infant parasympathetic regulation was assessed using baseline RSA during a neutral resting period. At 18 months, toddler behavioral dysregulation was evaluated using the Infant-Toddler Social Emotional Assessment. We tested direct and indirect pathways among prenatal maternal emotion dysregulation, postnatal parenting stress, infant baseline RSA, and toddler behavioral dysregulation with structural equation models.</p><p><strong>Results: </strong>Higher prenatal maternal emotion dysregulation was associated with greater postnatal parenting stress and lower infant baseline RSA. Postnatal parenting stress was concurrently associated with higher infant baseline RSA and higher toddler behavioral dysregulation. Infant RSA was not directly associated with toddler behavioral dysregulation. Parenting stress partially accounted for associations between prenatal maternal emotion dysregulation and toddler behavioral outcomes.</p><p><strong>Conclusion: </strong>This study provides evidence for prospective indirect pathways in which maternal emotion dysregulation during pregnancy contributes to elevated parenting stress in infancy, which is linked to both infant parasympathetic regulation and toddler behavioral dysregulation. Although prenatal maternal emotion dysregulation was associated with infant baseline RSA, infant RSA was not associated with toddler dysregulation, suggesting partly distinct pathways of physiological and behavioral regulation development. These findings highlight pregnancy and infancy as important periods in early child development.</p>","PeriodicalId":15277,"journal":{"name":"Journal of child and adolescent psychopharmacology","volume":" ","pages":"443-453"},"PeriodicalIF":1.8,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13372060/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148301905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Fluoxetine on Cognitive Functioning in Children with Down Syndrome: A Prospective Open-Label Exploratory Study of Safety and Efficacy.","authors":"Iris Scala, Carmela Bravaccio, Maria Marino, Oriana Scicolone, Valeria Maffettone, Maria Pia Riccio, Gaetano Terrone, Dario Cattaneo, Emilio Clementi, Renata Bartesaghi, Pietro Strisciuglio","doi":"10.1177/10445463261458603","DOIUrl":"10.1177/10445463261458603","url":null,"abstract":"<p><strong>Background: </strong>Down syndrome (DS) is a major genetic cause of intellectual disability. In an animal model of DS, fluoxetine was shown to restore brain architecture and cognitive performance, acting primarily on the hippocampus, with effects persisting after treatment discontinuation. In this translational study, we assessed the safety and tolerability of fluoxetine at the standard labeled dose and explored selected efficacy endpoints to inform future clinical trials.</p><p><strong>Methods: </strong>The study was approved as a phase I, open-label study. Participants with full trisomy 21 received fluoxetine (10 mg/day) for 6 months, followed by a 6-month observation period. The primary endpoint, safety and tolerability, was evaluated through clinical examinations, biochemistry, plasma fluoxetine and norfluoxetine levels, electroencephalography, and electrocardiography at multiple time-points. As a secondary efficacy endpoint, we selected a set of cognitive tests to explore hippocampus-dependent functions and adaptive behavior.</p><p><strong>Results: </strong>Fourteen children with DS (8.1 ± 1.24 years; range 6-10) were enrolled, and 12 completed the 12-month study. No serious or severe adverse events (AEs) occurred. All AEs resolved without sequelae. Short-term terminal insomnia was observed in two patients. Neuropsychological assessments revealed improvements in visuospatial processing tasks during the study. Analysis of adaptive behavior suggested enhanced expression skills.</p><p><strong>Conclusions: </strong>These findings indicate that fluoxetine is safe in children with DS. The association with terminal insomnia warrants specific investigation in future trials and strategies to optimize tolerability are discussed. Efficacy analyses highlight the visuospatial processing domain as potentially responsive to treatment, supporting further research.</p>","PeriodicalId":15277,"journal":{"name":"Journal of child and adolescent psychopharmacology","volume":" ","pages":"432-442"},"PeriodicalIF":1.8,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148204970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond the Wait-and-See: Data-Driven Decision Points for Guiding Selective Serotonin Reuptake Inhibitor Treatment and Cognitive Behavioral Therapy in Pediatric Anxiety Disorders.","authors":"Julia N Stimpfl, Jeffrey A Mills, Katherine K Dahlsgaard, Tara S Peris, John C Piacentini, John T Walkup, Jeffrey R Strawn","doi":"10.1177/10445463261462882","DOIUrl":"10.1177/10445463261462882","url":null,"abstract":"<p><strong>Objectives: </strong>To identify early markers of acute treatment response among youth with anxiety disorders receiving cognitive behavioral therapy (CBT), selective serotonin reuptake inhibitor (SSRI) monotherapy, or their combination.</p><p><strong>Background: </strong>Although many youth with anxiety disorders benefit from CBT or SSRIs, response trajectories vary. Identifying early indicators of nonresponse may guide sequencing strategies and improve timely treatment delivery.</p><p><strong>Methods: </strong>Using data from the Child/Adolescent Anxiety Multimodal Study, improvement trajectories were modeled for youth (age 7-17) randomized to sertraline monotherapy (<i>N</i> = 133), CBT monotherapy (<i>N</i> = 139), their combination (<i>N</i> = 140), and placebo (<i>N</i> = 76). Patients were stratified by percent change in Pediatric Anxiety Rating Scale (PARS) scores at multiple time points, and logarithmic and logistic time-trend regression models were used to estimate the probability of response. Receiver operating characteristic (ROC) analyses were used to identify thresholds of improvement for predicting response.</p><p><strong>Results: </strong>In the sertraline group, ≥25% improvement in PARS score at week 4 had a higher probability of response by week 12 (60.8%) than <25% improvement (31.7%, <i>p</i> = 0.001). In CBT-treated youth, week 4 PARS improvement was less predictive of response, with ≥25% improvement predicting a 47.9% chance of response compared with 28.6% for <25% improvement (<i>p</i> = 0.025). In the combined treatment, ≥25% improvement predicted a73.3% probability of response, whereas <25% improvement yielded a 51.3% likelihood of response (<i>p</i> < 0.001). ROC analyses similarly suggested that week 4 improvement in PARS scores in the CBT group had near equivocal predictive value, though this improved by week 6 to levels comparable to those of the other treatment groups. At week 6, roughly 25% improvement in PARS score in the combined treatment had the best sensitivity and specificity for predicting response.</p><p><strong>Conclusions: </strong>Early improvement can predict treatment response in youth with anxiety disorders receiving sertraline monotherapy or combination treatment (sertraline and CBT). Conversely, the absence of early improvement in CBT-treated youth does not reliably predict treatment nonresponse. Treatment-specific thresholds may inform clinical decision making, and support earlier SSRI optimization while allowing more time to observe CBT-related gains.</p>","PeriodicalId":15277,"journal":{"name":"Journal of child and adolescent psychopharmacology","volume":" ","pages":"414-422"},"PeriodicalIF":1.8,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148360949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Letter:</i> Caregiver-Reported Monitoring of Catatonia in Autistic Adolescents: An Outpatient Measurement-Based Approach.","authors":"Christina V Raghunandan, Sarah Mohiuddin, Neera Ghaziuddin","doi":"10.1177/10445463261484457","DOIUrl":"10.1177/10445463261484457","url":null,"abstract":"","PeriodicalId":15277,"journal":{"name":"Journal of child and adolescent psychopharmacology","volume":" ","pages":"10445463261484457"},"PeriodicalIF":1.8,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148840458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Affective Neuroscience Personality Scales as Indicators of SSRI Treatment Response in Youths with Major Depressive Episodes: A Retrospective Cohort Study.","authors":"Dohyeong Lee, Minseok Lee, Kenneth L Davis, Kukju Kweon","doi":"10.1177/10445463261477334","DOIUrl":"https://doi.org/10.1177/10445463261477334","url":null,"abstract":"<p><strong>Background: </strong>We examined whether the Affective Neuroscience Personality Scales (ANPS), personality traits grounded in neurobiologically defined primary emotions, are associated with selective serotonin reuptake inhibitor treatment response in youths with major depressive episodes.</p><p><strong>Methods: </strong>This retrospective cohort study analyzed medical records from 142 youths (aged 12-20) at a university hospital. The primary outcome was the Clinical Global Impression (CGI) scale; secondary outcomes were the Children's Depression Inventory (CDI) and the Screen for Child Anxiety Related Emotional Disorders (SCARED). Outcomes were assessed at baseline, 3, and 6 months; demographic, developmental, clinical, and trauma covariates were recorded. Treatment response was defined as a CGI-I score ≤2 at 6 months.</p><p><strong>Results: </strong>Multivariable logistic regression revealed that higher baseline ANPS SADNESS (odds ratio [OR] = 0.92, <i>p</i> = 0.033) and CARE (OR = 0.93, <i>p</i> = 0.043) scores were significantly associated with a lower likelihood of achieving treatment response (CGI-I ≤2). Linear mixed models revealed that higher SADNESS (β = 0.007, <i>p</i> = 0.031) and CARE (β = 0.009, <i>p</i> = 0.005) were associated with a slower rate of improvement in the CGI-S. Additionally, SADNESS and CARE scores were associated with overall CDI and SCARED severity, respectively.</p><p><strong>Conclusions: </strong>These findings suggest that ANPS SADNESS and CARE may inform personalized treatment approaches in youths with major depressive episodes; however, the retrospective single-center design limits causal inference and the Korean ANPS remains in early stages of psychometric validation in adolescents, underscoring the need for prospective multicenter validation.</p>","PeriodicalId":15277,"journal":{"name":"Journal of child and adolescent psychopharmacology","volume":" ","pages":"10445463261477334"},"PeriodicalIF":1.8,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148712405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}